Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
81 hedge funds and large institutions have $540M invested in Revance Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
17% more capital invested
Capital invested by funds: $463M → $540M (+$77M)
9% more funds holding
Funds holding: 74 → 81 (+7)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.27M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$2.9M |
| 3 |
JP Morgan Chase
New York
|
+$2.72M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.67M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.42M |
| 2 |
PC
PointState Capital
New York
|
-$2.51M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.22M |
| 4 |
UBV
United Bank (Virginia)
Vienna,
Virginia
|
-$1.06M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$837K |
RVNC Hedge Fund Activity: Q4 2016 in Review
81 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2016, worth a combined $540M — up 17% from $463M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RVNC positions and 6 closed out — a net gain of 8 holders — while 31 added to existing stakes and 20 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $3.27M. The largest seller was Wellington Management Group, cutting an estimated $4.42M.
- 81 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2016, up from 74 in Q3 2016.
- Funds reported $540M of Revance Therapeutics, Inc. stock for Q4 2016, up 17% quarter-over-quarter.
- 14 funds opened new Revance Therapeutics, Inc. positions in Q4 2016 and 6 closed out, a net change of +8 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2016 was ArrowMark Colorado Holdings, an estimated $3.27M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2016 was Wellington Management Group, an estimated $4.42M sold.
Based on aggregated 13F filings for Q4 2016.